Patent application number | Description | Published |
20100331283 | Mitotic kinesin inhibitors and methods of use thereof - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 12-30-2010 |
20110124878 | KINASE INHIBITORS AND METHODS OF USE THEREOF - A compound of Formula II | 05-26-2011 |
20120157439 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 06-21-2012 |
20120157452 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [FORMULA I] | 06-21-2012 |
20130018033 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 01-17-2013 |
20130131039 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES - Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R | 05-23-2013 |
20140018399 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 01-16-2014 |
Patent application number | Description | Published |
20080242656 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1) | 10-02-2008 |
20080261994 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 10-23-2008 |
20080306258 | Cyclopropane compounds and pharmaceutical use thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 12-11-2008 |
20100105894 | Cyclopropane compounds and pharmaceutical use thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 04-29-2010 |
20110201651 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 08-18-2011 |
20120270803 | Mitotic Kinesin Inhibitors and Methods of Use Thereof - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 10-25-2012 |
Patent application number | Description | Published |
20110092479 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 04-21-2011 |
20110110889 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 05-12-2011 |
20140094603 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 04-03-2014 |
Patent application number | Description | Published |
20100145750 | Evaluating Service Oriented Architecture Governance Maturity - Evaluating service oriented architecture (‘SOA’) governance maturity including receiving, from a plurality of predetermined stakeholders in the SOA for a plurality of SOA governance capabilities, a stakeholder assessed value representing the current maturity of each of the plurality of SOA governance capabilities; determining, for each of the plurality of SOA governance capabilities in dependence upon the plurality of stakeholder assessed values from the stakeholders, a capability value for each of the plurality of SOA governance capabilities; assigning each of the SOA governance capabilities to a domain; determining, in dependence upon the capability values for each of the plurality of SOA governance capabilities of each domain, a domain maturity value for each domain; and communicating the domain maturity value for each domain to the predetermined stakeholders of the SOA. | 06-10-2010 |
20100161454 | Augmenting Service Oriented Architecture Governance Maturity - Augmenting service oriented architecture (‘SOA’) governance maturity including receiving an evaluation of the maturity of the governance of the SOA; identifying, for each governance capability in dependence upon the evaluation of the maturity of the governance capability, one or more predefined risks to the SOA; establishing, for each governance capability in dependence upon the predefined risks to the SOA, a risk value representing the severity of the predefined risks; selecting, for each governance capability in dependence upon the evaluation of the maturity of the governance of the SOA and the predefined risk value, one or more governance work products; and communicating to predetermined stakeholders in the SOA the one or more predefined risks to the SOA identified for each governance capability, the risk value established for each governance capability, and the governance work products selected for each governance capability. | 06-24-2010 |
20120143777 | USING DOCUMENTATION PLANS FOR SOA GOVERNANCE - A method, system, and computer program product for using documentation plans for service oriented architecture governance. In an example embodiment, the method includes implementing a structured documentation plan in a SOA governance tool using a computer processor. The structured documentation plan includes a set of documentation types and a set of governance policies for at least one documentation type from the set of documentation types. | 06-07-2012 |
20120221377 | Augmenting Service Oriented Architecture Governance Maturity - Augmenting service oriented architecture (‘SOA’) governance maturity including receiving an evaluation of the maturity of the governance of the SOA; identifying, for each governance capability in dependence upon the evaluation of the maturity of the governance capability, one or more predefined risks to the SOA; establishing, for each governance capability in dependence upon the predefined risks to the SOA, a risk value representing the severity of the predefined risks; selecting, for each governance capability in dependence upon the evaluation of the maturity of the governance of the SOA and the predefined risk value, one or more governance work products; and communicating to predetermined stakeholders in the SOA the one or more predefined risks to the SOA identified for each governance capability, the risk value established for each governance capability, and the governance work products selected for each governance capability. | 08-30-2012 |
20130340026 | Association of Service Policies Based on the Application of Message Content Filters - A method for associating service policies based on application of message content filters to messages sent by a consumer may include receiving a message in which the message relates to a service accessible via a network and access to the service is restricted by a policy enforcement runtime. The method may further include applying at least one message content filter to the message content received to extract information indicative of a message flow associated with a configured policy attachment and correlating the message flow to a selected policy regarding consumer access to the service. The method may further include enforcing the selected policy relative to access to the service by the consumer. | 12-19-2013 |
20130340029 | ASSOCIATION OF SERVICE POLICIES BASED ON THE APPLICATION OF MESSAGE CONTENT FILTERS - A method for associating service policies based on application of message content filters to messages sent by a consumer may include receiving a message in which the message relates to a service accessible via a network and access to the service is restricted by a policy enforcement runtime. The method may further include applying at least one message content filter to the message content received to extract information indicative of a message flow associated with a configured policy attachment and correlating the message flow to a selected policy regarding consumer access to the service. The method may further include enforcing the selected policy relative to access to the service by the consumer. | 12-19-2013 |